Dr. Reddy’s Lab’s Q2FY25Results

• Dr. Reddy’s Lab reported a 6% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter ended Sept (Q2FY25). On a year-on-year (YoY) basis, it witnessed a growth of 16%.
• Its expenses for the quarter were up by 7% QoQ and 21% YoY.
• The net profit declined 4% QoQ and 9% YoY.
• The earnings per share (EPS) of Dr. Reddy’s Lab stood at 15.1 during Q2FY25.

Dr. Reddy’s Lab’s Financial Statements for Q2FY25:

Financials:

Revenues: ₹80,162 Mn, up 17% YoY, 4% QoQ.
Gross Margin: 59.6%, higher than Q2FY24’s 58.7% but lower than Q1FY25’s 60.4%.
SG&A Expenses: ₹23,007 Mn, up 22% YoY, 1% QoQ.
R&D Expenses: ₹7,271 Mn, constituting 9.1% of revenues.
EBITDA: ₹22,803 Mn, representing 28.4% of revenues.
Profit before Tax: ₹19,167 Mn, flat YoY, up 2% QoQ.
Profit after Tax (before Non-Controlling Interest): ₹13,415 Mn, down 9% YoY, 4% QoQ.
Profit after Tax (attributable to Equity Holders): ₹12,553 Mn, down 15% YoY, 10% QoQ.

Management Commentary:

Co-Chairman & MD, G V Prasad:

• Achieved strong growth and maintained business momentum.
• Progressed on future growth drivers.
• Operationalised a venture with Nestlé.
• Completed the acquisition of Nicotinell® and related brands.
• Committed to enhancing efficiency and strengthening core businesses.
• Focused on positively impacting patient lives through science and innovation.

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results